Zen-Bio, Inc.
Durham, NC Doing business as Zenbio Part of Bioivt, LLC
- UEI
- LQS2WJFBBUQ3
- CAGE
- 3MZW4
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Bioivt, LLC, ranks #45 in NAICS 325414
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Woodbury, NY
L2BGKGC6LJW7
-
Parent
Woodbury, NY
L2BGKGC6LJW7
- SAM.gov registration date
- Physical address
- 3920 S Alston Ave, Durham, NC 27713, USA
- Website
- zen-bio.com
- Founded
- 1995
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $49,395 |
| FY2025 | $79,797 |
| FY2024 | $87,535 |
| FY2023 | $132,380 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $49,395 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Lampire Biological Labs Inc. | Ottsville, PA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Vitalant Research Institute | Scottsdale, AZ | 621511 Medical Laboratories |
| Shared Service Center | Charlotte, NC | 621991 Blood and Organ Banks |
| Lifesouth Community Blood Centers Inc. | Gainesville, FL | 621991 Blood and Organ Banks |
| Versiti Wisconsin Inc. | Milwaukee, WI | 621991 Blood and Organ Banks |
About the company
Zen-Bio, Inc., doing business as Zenbio, manufactures specialized human blood products and related biological materials for federal research and public health agencies, operating as a prime contractor on full-and-open federal contracts with no set-aside posture. Zenbio is a for-profit manufacturer headquartered in Durham, North Carolina, and is a wholly owned subsidiary of Bioivt, LLC, a biologics firm based in Woodbury, New York. The vendor competes exclusively in open market procurement across eleven distinct federal customer agencies, with no SBA certifications or set-aside activity in the source record.
Zenbio's federal work centers on procurement of blood products and specialized cell cultures for disease research, surveillance, and therapeutic development. The vendor holds a single-award Blanket Purchase Agreement with the CDC's Pittsburgh office for blood unit procurement running through September 19, 2025. Representative recent prime work includes a $250,515 definitive contract awarded by the Defense Health Agency on March 19, 2026, for human blood to support malaria parasite culture research at place of performance Durham, North Carolina, with contract ceiling extending to February 22, 2031; a $87,624 BPA call from CDC Pittsburgh in January 2025 for blood products to support disease monitoring and prevention; and a $19,044 purchase order from the National Heart, Lung, and Blood Institute in July 2024 for cord blood CD34+/CD133+ cells to develop novel gene therapy strategies.
Customer concentration is weighted heavily to the National Institutes of Health and the CDC. The top five customer organizations by award count account for 74% of recent awards, with the National Institutes of Health leading at 16 awards, followed by CDC Pittsburgh at 5 awards ($509 thousand combined potential value). The top customers by potential value are dominated by CDC Pittsburgh ($509 thousand across 5 awards) and the Defense Health Agency ($449 thousand across 2 awards), a divergence from the count ranking that reflects the higher ceiling values on the DHA definitive contract. Zenbio has worked with the National Institute on Aging, the National Center for Advancing Translational Sciences, the National Cancer Institute, and the Army Medical Command. Three task orders carry $221 thousand in combined potential value under BPA 75D30123A17284.
Activity remains sparse and episodic in the source window — one award in 2026, one in 2025, and two in 2024 — with a long historical tail dating to 2003. The vendor holds no subcontracting relationships in the source record and operates exclusively as a prime contractor. Combined obligated dollars across all 38 awards reach $15.4 million, substantially outpacing the combined potential value of $1.3 million, indicating heavy invoiced activity against prior-year contract ceilings. Zenbio's NAICS footprint is dominated by Biological Product (except Diagnostic) Manufacturing and traces secondary work in R&D consulting and medical laboratory services.
SBA capabilities narrative
Cultured human cell systems for drug discovery. Offering adipocytes, preadipocytes, visceral adipocytes, hepatocytes, skeletal myocytes, media, reagents, RNA, Assay development services, compound screeing services and extensive contract assay services.
Quick answers
Is Zen-Bio, Inc. registered in SAM.gov?
Yes. Zen-Bio, Inc.'s SAM.gov registration is active through May 27, 2027.
How much has Zen-Bio, Inc. received in federal contracts?
Federal contracts obligated $79,797 to Zen-Bio, Inc. in fiscal year 2025 and $349,107 in fiscal years 2023 through 2027.
How does Zen-Bio, Inc. rank among federal contractors?
Zen-Bio, Inc.'s parent company, Bioivt, LLC, ranked #45 in NAICS 325414 in FY2025.
What is Zen-Bio, Inc.'s most recent federal award?
Zen-Bio, Inc.'s most recent federal contract award is Human blood for research utilizing malaria parasite cultures (HT942626CE004), from Defense Health Agency, on March 19, 2026.
On GovTribe
See Zen-Bio, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors